Kullanım Kılavuzu
Neden sadece 3 sonuç görüntüleyebiliyorum?
Sadece üye olan kurumların ağından bağlandığınız da tüm sonuçları görüntüleyebilirsiniz. Üye olmayan kurumlar için kurum yetkililerinin başvurması durumunda 1 aylık ücretsiz deneme sürümü açmaktayız.
Benim olmayan çok sonuç geliyor?
Birçok kaynakça da atıflar "Soyad, İ" olarak gösterildiği için özellikle Soyad ve isminin baş harfi aynı olan akademisyenlerin atıfları zaman zaman karışabilmektedir. Bu sorun tüm dünyadaki atıf dizinlerinin sıkça karşılaştığı bir sorundur.
Sadece ilgili makaleme yapılan atıfları nasıl görebilirim?
Makalenizin ismini arattıktan sonra detaylar kısmına bastığınız anda seçtiğiniz makaleye yapılan atıfları görebilirsiniz.
 Görüntüleme 305
 İndirme 29
İlaca Bagli Olarak Cene Kemiklerinde Gorulen Osteonekroz (mronj): Derleme
2019
Dergi:  
Journal of Biotechnology and Strategic Health Research
Yazar:  
Özet:

Bisphosphonates are drugs that are increasingly used in osteoporous treatment and that slow down and even stop resorption process in bone. These drugs are also effectively used in treatment of Paget's disease and metabolic bone diseases, hypercalcemia, multiple myeloma and bone diseases associated with metastatic conditions. The most dangerous side effect may be the risk of causing osteonecrosis. This osteonecrosis due to bisphosphonate was first identified in 2002 by Marx and Stern by a group of patients receiving bisphosphonates in the mouth who were aware of the presence of exposed osteonecrotic bone areas that were not healing, not covered with mucosa. This osteonecrosis in the jaw bones due to the use of bisphosphonates has been published in literature as the name of BRONJ, which consists of combining  initials of ‘’Bisphosphonate Related Osteonecrosis of the Jaw’’. However, researches on this subject have increased, and this type of osteonecrosis isn’t only for bisphosphonate-derived drugs; chemotherapeutic drugs and derivatives such as denosumab, which are RANKL inhibitor, have been shown to be the cause. In 2014,  AAOMS updated the term ‘’Medication-Related Osteonecrosis of the Jaw (MRONJ)’’, which means osteonecrosis in jaw bones due to the drug, due to the need for regulation in naming. 

Anahtar Kelimeler:

Osteonecrosis (mronj) Seen In The Bone Of The Chest As Medication-related:
2019
Yazar:  
Özet:

Bisphosphonates are drugs that are increasingly used in osteoporosis treatment and that slow down and even stop the resorption process in the bone. These drugs are also effectively used in treatment of Paget's disease and metabolic bone diseases, hypercalcemia, multiple myeloma and bone diseases associated with metastatic conditions. The most dangerous side effect may be the risk of causing osteonecrosis. This osteonecrosis due to bisphosphonate was first identified in 2002 by Marx and Stern by a group of patients receiving bisphosphonates in the mouth who were aware of the presence of exposed osteonecrotic bone areas that were not healing, not covered with mucosa. This osteonecrosis in the jaw bones due to the use of bisphosphonates has been published in literature as the name of BRONJ, which consists of combining initials of "Bisphosphonate Related Osteonecrosis of the Jaw". However, researches on this subject have increased, and this type of osteonecrosis is not only for bisphosphonate-derived drugs; chemotherapeutic drugs and derivatives such as denosumab, which are RANKL inhibitors, have been shown to be the cause. In 2014, AAOMS updated the term 'Medication-Related Osteonecrosis of the Jaw (MRONJ)', which means osteonecrosis in the jaw bones due to the drug, due to the need for regulation in naming.

Anahtar Kelimeler:

Atıf Yapanlar
Bilgi: Bu yayına herhangi bir atıf yapılmamıştır.
Benzer Makaleler












Journal of Biotechnology and Strategic Health Research

Alan :   Sağlık Bilimleri

Dergi Türü :   Uluslararası

Metrikler
Makale : 302
Atıf : 721
2022 Impact/Etki : 0.231
Quarter
Sağlık Bilimleri Temel Alanı
Q1
32/188

Journal of Biotechnology and Strategic Health Research